Open AccessImmunogenicity and Safety of Yellow Fever Vaccination for 102 HIV‐Infected Patients
Author(s) -
Olivia Veit,
Matthias Niedrig,
Caroline ChapuisTaillard,
Matthias Cavassini,
Erik Mossdorf,
Patrick Schmid,
HiGung Bae,
Nadine Litzba,
Thomas Staub,
Christoph Hatz,
Hansjakob Furrer
Publication year - 2009
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/597006
Subject(s) - immunogenicity , medicine , virology , vaccination , human immunodeficiency virus (hiv) , yellow fever , immunology , population , yellow fever vaccine , virus , antibody , environmental health
Yellow fever vaccine (17DV) has been investigated incompletely in human immunodeficiency virus (HIV)-infected patients, and adequate immunogenicity and safety are of concern in this population.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom